

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA ISOTOPE & RADIATION CORPORATION**  
**中國同輻股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 1763)**

**VOLUNTARY ANNOUNCEMENT**

**CHINA ISOTOPE UNVEILING FUZHI INTELLIGENT NUCLEAR  
MEDICINE SYSTEM (V1.0) AT THE 2023 ANNUAL ACADEMIC  
CONFERENCE OF CHINESE SOCIETY OF NUCLEAR MEDICINE**

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, at the 2023 annual academic conference of Chinese Society of Nuclear Medicine (中華醫學會核醫學分會), the Company unveiled the Fuzhi Intelligent Nuclear Medicine System (v1.0) (輻智1.0智慧核醫學系統), six modules of which also made their debut in the industry, including smart patient care, smart nuclear pharmaceuticals management, smart department management, smart safety management, smart radionuclide ward, and smart operation and management.

The launch of Fuzhi Intelligent Nuclear Medicine System (v1.0) has garnered considerable attention from industry experts, and set a new milestone for promoting the regulated, standardised and intelligent high-quality development of nuclear medicine departments. It also marked the inauguration of China's first intelligent nuclear medicine demonstration base in Peking Union Medical College Hospital (北京協和醫院).

By order of the Board  
**China Isotope & Radiation Corporation**  
**Wang Suohui**  
*Chairman*

Beijing, the PRC, 26 September 2023

*As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.*